Acas LLC Sells 960 Shares of Pfizer Inc. (NYSE:PFE)

Acas LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 5.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,694 shares of the biopharmaceutical company’s stock after selling 960 shares during the period. Acas LLC’s holdings in Pfizer were worth $452,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of PFE. Investment Advisory Services Inc. TX ADV raised its stake in Pfizer by 1.6% during the 3rd quarter. Investment Advisory Services Inc. TX ADV now owns 20,097 shares of the biopharmaceutical company’s stock worth $667,000 after buying an additional 325 shares during the period. Trifecta Capital Advisors LLC increased its holdings in Pfizer by 3.7% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 325 shares during the period. Powers Advisory Group LLC boosted its position in shares of Pfizer by 2.4% in the 3rd quarter. Powers Advisory Group LLC now owns 13,759 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 329 shares in the last quarter. Confluence Wealth Services Inc. lifted its position in Pfizer by 0.5% in the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after acquiring an additional 342 shares in the last quarter. Finally, Carr Financial Group Corp increased its stake in shares of Pfizer by 3.3% in the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after purchasing an additional 355 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 2.4 %

Shares of PFE stock traded down $0.64 on Thursday, reaching $25.63. 9,448,029 shares of the stock were exchanged, compared to its average volume of 41,440,848. The stock has a market cap of $145.13 billion, a PE ratio of 72.94, a P/E/G ratio of 1.19 and a beta of 0.61. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a 50 day moving average price of $27.05 and a 200 day moving average price of $28.50.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. Pfizer’s revenue was down 41.3% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.55%. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Analyst Ratings Changes

A number of brokerages recently commented on PFE. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.